CN118307669A - 靶向usag-1分子的用于牙齿再生治疗的中和抗体 - Google Patents

靶向usag-1分子的用于牙齿再生治疗的中和抗体 Download PDF

Info

Publication number
CN118307669A
CN118307669A CN202410516861.9A CN202410516861A CN118307669A CN 118307669 A CN118307669 A CN 118307669A CN 202410516861 A CN202410516861 A CN 202410516861A CN 118307669 A CN118307669 A CN 118307669A
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
usag
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410516861.9A
Other languages
English (en)
Chinese (zh)
Inventor
高桥克
菅井学
时田义人
高木淳一
三原惠美子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Fukui
Kyoto University
The University of Osaka
Original Assignee
Osaka University NUC
University of Fukui
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, University of Fukui, Kyoto University filed Critical Osaka University NUC
Publication of CN118307669A publication Critical patent/CN118307669A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
CN202410516861.9A 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体 Pending CN118307669A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2019130153 2019-07-12
JP2019-130153 2019-07-12
JP2020-080723 2020-04-30
JP2020080723 2020-04-30
CN202080063186.9A CN114364694B (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体
PCT/JP2020/027127 WO2021010346A1 (ja) 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080063186.9A Division CN114364694B (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Publications (1)

Publication Number Publication Date
CN118307669A true CN118307669A (zh) 2024-07-09

Family

ID=74209883

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410516861.9A Pending CN118307669A (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN202080063186.9A Active CN114364694B (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080063186.9A Active CN114364694B (zh) 2019-07-12 2020-07-10 靶向usag-1分子的用于牙齿再生治疗的中和抗体

Country Status (6)

Country Link
US (1) US12655203B2 (cg-RX-API-DMAC10.html)
EP (1) EP4000633A4 (cg-RX-API-DMAC10.html)
JP (3) JP7572668B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220034176A (cg-RX-API-DMAC10.html)
CN (2) CN118307669A (cg-RX-API-DMAC10.html)
WO (1) WO2021010346A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116425870A (zh) * 2023-05-24 2023-07-14 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7572668B2 (ja) 2019-07-12 2024-10-24 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
US20240043841A1 (en) * 2020-02-21 2024-02-08 Kyoto University Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy
JPWO2023148894A1 (cg-RX-API-DMAC10.html) * 2022-02-03 2023-08-10

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8176798A (en) * 1997-06-30 1999-01-19 Genetics Institute Inc. Secreted proteins
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
SI3345607T1 (sl) * 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CN101925611A (zh) 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
US20120288507A1 (en) * 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
PT2832365T (pt) * 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
CA3032826A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
JP7572668B2 (ja) 2019-07-12 2024-10-24 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116425870A (zh) * 2023-05-24 2023-07-14 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用
CN116425870B (zh) * 2023-05-24 2026-05-22 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Also Published As

Publication number Publication date
US12655203B2 (en) 2026-06-16
JP7572668B2 (ja) 2024-10-24
JP2026081263A (ja) 2026-05-18
US20220259298A1 (en) 2022-08-18
EP4000633A4 (en) 2024-02-21
KR20220034176A (ko) 2022-03-17
CN114364694B (zh) 2024-05-10
JP2021176829A (ja) 2021-11-11
WO2021010346A1 (ja) 2021-01-21
JP2025004094A (ja) 2025-01-14
CN114364694A (zh) 2022-04-15
EP4000633A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
CN114364694B (zh) 靶向usag-1分子的用于牙齿再生治疗的中和抗体
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
TW202438531A (zh) 抗ccr8抗體及其用途
JP7627469B2 (ja) 抗ｔｉｇｉｔ抗体、その調製方法と応用
BR112020017296A2 (pt) Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
US20180208648A1 (en) Gdf11 binding proteins and uses thereof
US12552873B2 (en) Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2017532037A (ja) ヒト化抗ｏｘ４０抗体及びその使用
JP2020524000A (ja) 抗ｂｃｍａ重鎖のみ抗体
CN110494449B (zh) Alt-803与抗cd38抗体组合用于癌症治疗
CN1344275A (zh) 用淀粉样蛋白抗体除去淀粉样蛋白的方法
KR20190015705A (ko) 타우 면역요법
US10556947B2 (en) Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor
CN113412130A (zh) 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向
AU2014305658A1 (en) An antibody therapy for amyloid beta disease
FR3075200A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
KR20230026489A (ko) 소르틸린을 인지하는 항체
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
JPH07509776A (ja) Ｂ型肝炎ウイルス受容体活性を有するエンドネキシン■由来ポリペプチド，並びに診断および製剤組成物におけるその用途
US20250136674A1 (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
HK40073445A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40107636A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40073445B (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40114319A (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107636

Country of ref document: HK